Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase’s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol ‘TTPH.’ Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Company Growth (employees)
Type
Public
HQ
Watertown, US
Founded
2006
Size (employees)
69 (est)
Website
tphase.com
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Key People at Tetraphase Pharmaceuticals

Patrick Gage

Patrick Gage

Chairman

Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
110 480 Arsenal St

Tetraphase Pharmaceuticals Data and Metrics

Tetraphase Pharmaceuticals Financial Metrics

Tetraphase Pharmaceuticals's revenue was reported to be $5.1 m in 2016 which is a 56% decrease from the previous period.
Numbers are in $, USD

Revenue (Y, 2016)

5.1 m

Revenue growth (Y, 2015 - Y, 2016), %

(56%)

Net income (Y, 2016)

(77.5 m)

EBIT (Y, 2016)

(77.8 m)

Market capitalization (22-Jun-2017)

299.1 m

Closing share price (22-Jun-2017)

8

Cash (31-Dec-2016)

142.1 m
Tetraphase Pharmaceuticals's current market capitalization is $299.1 m.
FY, 2013FY, 2014Y, 2015Y, 2016

Revenue

18.3 m9.1 m11.7 m5.1 m

Revenue growth, %

(50%)28%(56%)

Operating expense total

131.1 m74.9 m94.7 m83 m

EBIT

(112.8 m)(65.8 m)(83 m)(77.8 m)

EBIT margin, %

(617%)(723%)(710%)(1513%)

Interest expense

1.7 m1 m231 k231 k

Interest income

10 k17 k42 k350 k

Net Income

(119.7 m)(66.7 m)(83.2 m)(77.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

102.7 m121 m205.9 m142.1 m

Accounts Receivable

1.7 m3.5 m4.2 m1.8 m

Inventories

1 m2.1 m3.7 m6.6 m

Current Assets

105.4 m126.6 m213.8 m150.5 m

PP&E

235 k300 k943 k1.1 m

Total Assets

105.9 m127.2 m214.9 m151.7 m

Accounts Payable

1.9 m4.1 m2.9 m2.6 m

Current Liabilities

13.2 m17.3 m10.7 m11.5 m

Additional Paid-in Capital

207.5 m295 m473.7 m487.1 m

Retained Earnings

(186.5 m)(269.7 m)(347.1 m)

Total Equity

87.8 m108.6 m204.1 m140.1 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.6 m)(66.7 m)(83.2 m)(77.5 m)

Depreciation and Amortization

129 k124 k193 k282 k

Accounts Receivable

746 k(1.8 m)(693 k)2.4 m

Inventories

(154 k)(1.2 m)(1.5 m)

Accounts Payable

310 k2.2 m(1.2 m)(302 k)

Cash From Operating Activities

(24.5 m)(57.6 m)(76.7 m)(63.8 m)

Purchases of PP&E

(129 k)(191 k)(838 k)(393 k)

Cash From Investing Activities

(129 k)(191 k)(838 k)(393 k)

Cash From Financing Activities

118.3 m76.1 m162.4 m333 k

Interest Paid

1.1 m945 k363 k363 k
Y, 2016

Financial Leverage

1.1 x

Tetraphase Pharmaceuticals Market Value History

Tetraphase Pharmaceuticals Online and Social Media Presence

Tetraphase Pharmaceuticals Company Life and Culture

You may also be interested in